

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number  
**WO 2005/047251 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 207/16, 207/14**

(21) International Application Number:  
**PCT/KR2004/002929**

(22) International Filing Date:  
12 November 2004 (12.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10-2003-0079799  
12 November 2003 (12.11.2003) KR  
10-2004-0065820 20 August 2004 (20.08.2004) KR

(71) Applicants (*for all designated States except US*): **LG LIFE SCIENCES LTD.** [KR/KR]; LG Twin Tower, East Tower, 20, Yoido-dong, Youngdeungpo-gu, Seoul 150-010 (KR). **YAMANOUCHI PHARMACEUTICAL CO., LTD.** [JP/JP]; 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LEE, Koo** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **PARK, Heui-Sul** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **AHN, In-Ae** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **YOO, Hyun-Ju** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **KIM, Jong-Yup** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **CHOI, Deog-Young** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **YIM, Hyeon-Joo** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **CHUNG, Kyung-Ha** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon

305-380 (KR). **SHIM, Dong-Sup** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **LEE, Sang-Kyun** [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **KONDOH, Yutaka** [JP/JP]; 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 (JP). **HIRABAYASHI, Ryoji** [JP/JP]; 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 (JP). **HONDA, Shugo** [JP/JP]; 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 (JP). **KAKU, Hidetaka** [JP/JP]; 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 (JP). **SHISHIKURA, Jun-Ichi** [JP/JP]; 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 (JP). **ITO, Hiroyuki** [JP/JP]; 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 (JP). **KURAMA, Takeshi** [JP/JP]; 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 (JP).

(74) Agent: **CHOI, Kyu-Pal**; Halla Classic Building 4F, 824-11, Yeoksam-dong, Kangnam-gu, Seoul 135-080 (KR).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report:

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MELANOCORTIN RECEPTOR AGONISTS

(57) Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

WO 2005/047251 A1